

Reprograming the immune response against cancer

October 16, 2025

METX: CSE | FSE:Q9T

FORWARD-LOOKING STATEMENT

THIS PRESENTATION IS CONFIDENTIAL AND IS BEING SUPPLIED TO YOU SOLELY FOR YOUR INFORMATION AND MAY NOT BE REPRODUCED, FURTHER DISTRIBUTED TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE.

This Presentation does not constitute an offer to sell or a solicitation of offers to buy common shares or other securities, assets or products of any company and is not intended to form the basis of any investment decision.

Certain information in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact are forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend", "estimate" or the negative of these terms and similar expressions. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements in this presentation include, but are not limited to, statements regarding the Company's patent protection, research plans, the intended outcomes of the research, the intended benefits and applications of the Company's technology, the Company's plans for development of its business, plans for potential first-in-human clinical trials, opportunities to explore earlier stage drug discovery and to enhance the Company's drug pipeline, its reliance on third-party collaborators, and regarding potential in-licensing and partnership opportunities. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including risks related to factors beyond the control of the Company, that the results of the testing are not favorable or consistent with results to date, G-CSF proves to be an unsuitable target to treat cancer, that the Company's mRNA or in vivo CAR candidates prove ineffective during testing, that the Company's business may not develop as set out in this presentation, that the Company does not proceed with human clinical trials or that the results of such trials, if any, are not favorable, that the Company does not acquire the necessary regulatory approvals, that the Company does not complete any licensing or partnership agreements or that if such agreements are completed that the terms may not be favorable to the Company, that the Company does not have sufficient funds to advance its business plan, and such other risks described in the Company's public disclosure and risks which are inherent to businesses of this nature. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ from forward-looking statements.

The assumptions of the Company, although considered reasonable by it at the time of preparation, may prove to be incorrect. In addition, forward-looking statements necessarily involve known and unknown risks, including, without limitation, the Company's discretion in the use of its available funds; the Company has a limited operating history; the Company operates in a new industry and the market is unknown; the Company lacks operating cash flow; there is uncertainty about the Company and the Company's ability to continue as a going concern; the financial position of the Company may differ from the expectations of management; the Company may experience delays if any of its candidates reach clinical trial; the Company may be unsuccessful if it pursues partnership at the pre-clinical stage; the Company may obtain negative results from studies or trials; there is a lack of clinical data supporting the Company's prodrug candidates and data obtained may not be predictive of future results; the Company may not be able to commercialize its drug candidates and generate revenues; the Company is highly dependent on specialized personnel; the Company may expend its capital resources on failed drug candidates; the Company lacks diversity in its plans; the Company will incur significant costs in its growth; the Company may not be able to protect its intellectual property or have to defend its intellectual property rights; the Company may face competition from competitors with more resources; the Company may not be able to obtain future financing, as required; future collaboration agreements of the Company may not be favourable or available; the Company is dependent on regulatory approvals and designations; the Company may not be able to engage a viable manufacturer; the Company continues to rely on third parties to perform research and development; the Company's cost and timeline estimates may be inaccurate; and other business risks common for businesses like the Company's. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this presentation are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

ABOUT US

Myeloid Enhancement (ME) Therapeutics is a biotechnology company involved in the discovery and development of novel immuno-oncology therapeutics which reprogram the tumor microenvironment to fight cancer. Our focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells to enhance anti-cancer immunity.



TARGETING THE TUMOR MICROENVIRONMENT

MYELOID CELL REPROGRAMING IN VIVO

MYELOID CELLS AND CANCER ASSOCIATED FIBROBLASTS BLOCK T CELL RESPONSES

- *Myeloid cells (macrophages, myeloid derived suppressor cells) and Cancer associated fibroblasts (CAFs) are a major part of the tumor microenvironment (TME)*
- *Myeloid cells and CAFs interfere with T cell activation by expressing inhibitory receptors and producing tumor supporting factors*
- *Myeloid cell reprogramming → engineering myeloid cells in the tumor can activate anti-tumor immunity*
  - *Blocking suppressive proteins*
  - *Killing CAFs*
  - *Stimulating T cell activation*
  - *Killing tumor cells*
- *Goal is to unlock anti-cancer immunity in non-responders*



THE LANDSCAPE

Our drug candidates target the immune system and not the cancer directly so they may be used in several cancer types.



BREAST CANCER

*(316,950 estimated cases in the U.S. in 2025)**

LUNG CANCER

*(226,650 estimated cases in the U.S. in 2025)**

COLORECTAL CANCER

*(154,270 estimated cases in the U.S. in 2025)**

PRICING AND TARGET MARKET

Current Immuno-Oncology (IO) drugs (Keytruda, Opdivo) = ~ *$190,000***

Unlocking small fraction of the market = significant revenue potential

* seer.cancer.gov

**https://www.goodrx.com/drugs/biologics/resources-for-affording immunotherapy?srsltid=AfmBOooM6pCr655uPybQ75QoRGvlk2XUi_I7anByCZZ2Dm3fcFtnCswT

INNOVATIVE PIPELINE

- *In vivo Pan- chimeric antigen receptor (CAR) program*
  - *CAR expression in myeloid and T cells*
  - *CD19/CD22 dual CAR for B cell leukemias*
  - *TME targeting CAR for solid tumors*
- *Therapeutic mRNA to modulate tumor microenvironment (TME)*
  - *Stimulate immune cell recruitment and activation*
  - *Make cold tumors hot*
  - *Targeting key scientifically validated pathways*
- *Humanized antibody to block activity of G-CSF*
  - *Reduces immune suppression, increases T cell activity, and overcomes resistance to VEGF therapy*
  - *Position as a combination therapy with PD-1/VEGF bi-specific*

IN VIVO IMMUNE CELL REPROGRAMMING

- *In vivo therapeutic mRNA delivery to modulate tumor microenvironment (TME)*
  - *Creating 'hot' tumors*
  - *Targeted delivery of stimulatory proteins directly to the TME*
  - *Validated targets in development*
  - *Developing tumor-specific expression*
  - *Reduce systemic toxicity of key targets*
- *In vivo chimeric antigen receptor (CAR) delivery to myeloid cells and T cells (Pan-CAR)*
  - *Engineering immune cells to recognize and destroy tumor cells or tumor supporting cells*
  - *Potential to improve solid tumor response*
    - *Myeloid cells can infiltrate some tumors better than T cells*





MRNA DELIVERY

Partnered with NanoVation Therapeutics (NTx)

- *Long circulating Lipid Nanoparticle (LNP) addresses the key extrahepatic delivery challenge in mRNA delivery*
  - *Accumulates in the tumor microenvironment*
  - *Increases immune cell targeting (myeloid cells, T cells, or both)*

- *NTx co-founded by world experts in LNP technology – Dr. Pieter Cullis, Dr. Dominik Witzigmann, and Dr. Jayesh Kulkarni*

- *Recent partnership with Novo Nordisk*

- *Targeting of LNPs to immune cells through changes in ionizable lipids and helper lipids*
  - *Does not require protein based LNP modifications*
  - *Potentially easier to manufacture than competing approaches*

IN VIVO PIPELINE

CD19/CD22 in vivo Pan-CAR

- *CAR expression in both T cells and myeloid cells*
- *dual antigen targeting approach for B-ALL and DLBCL*
- *Novel CD22 nanobody binder being derisked in a Phase 1 clinical study*
- *CD19 targeting already derisked clinically*
- *Pan-CAR approach may lead to deeper B cell depletion in tissue (CAR macrophages form large part of TME)*
- *Safer (transient) and more cost effective than autologous CAR approach*
- *Potentially enhanced durability through repeat dosing*
- *Dual target CAR approach can reduce antigen escape, achieve broader tumor coverage, enable salvage and increase depth of response vs single target CAR*
- *Potential to apply to B cell depletion for autoimmune disease*





IN VIVO PIPELINE

Therapeutic STING activating mRNA

- *STING is a key target for creating a hot TME (increasing immune cell recruitment, stimulating antigen presentation, overcoming resistance to checkpoint)*
- *Several small molecule STING activators in clinical trials*
- *So far all have been unsuccessful due to toxicity or dose limitations (systemic dosing is difficult)*
- *Our STING activating mRNA is delivered into the TME and leads to anti-tumor activity*
- *Advantage of our approach:*
  - *Tumor targeted delivery (less systemic toxicity)*
  - *May overcome STING downregulation in tumors*

PLATFORM ADVANTAGES

- *mRNA platform adds significant value to company*
- *Rapid design and testing of novel therapies based on cutting edge science*
- *Proprietary mRNA design allows for targeted expression of protein of interest to modulate cancer or autoimmune conditions*
- *Lower off-target effects and potentially greater safety*
- *Partnered LNP delivery technology is potentially best in class for delivery to immune cells*
- *Relative ease of clinical development*
- *Faster timelines to clinical trials*





ANTI-G-CSF ANTIBODY

- *Blocking G-CSF reduces myeloid suppressor cells, increases T cells, and overcomes resistance to VEGF therapies*
- *High affinity neutralizing antibody discovered and tested*
  - *Non-human primate studies completed demonstrating good pharmacology without observable toxicity (neutropenia)*
  - *Cell line development underway*
- *Potential Phase I/II study in metastatic colorectal cancer to test single agent efficacy and overcoming resistance to VEGF*
- *If G-CSF blockade can overcome VEGF resistance in clinical setting it may become important target in context of PD-1/VEGF bi-specifics*

DEVELOPMENT PLAN

- *In vivo Pan-CAR proof of concept studies 2026*
  - *Initiate non-human primate (NHP) studies in late 2025/early 2026*
  - *Non-GLP toxicology early 2026*
  - *Potential IND late 2026*
- *Therapeutic mRNA program*
  - *In vivo mouse efficacy studies late 2025/ early 2026*
  - *NHP toxicology mid-2026*
  - *Potential IND late 2026*
- *Anti-G-CSF antibody program*
  - *Cell line development complete early 2026*
  - *Pre-IND meeting early 2026*
- *Acquiring Nasdaq direct listing 2026*
  - *Increase investor base and liquidity*

OUR TEAM

SALIM DHANJI | PhD, CEO, Director & Founder

- *Former director of preclinical research at Qu Biologics*
- *Industry and academic expertise in cancer, autoimmunity and inflammation*

KENNETH HARDER | PhD, Director

- *Associate Professor at University of British Columbia*
- *Expertise in myeloid cell biology, lipid nanoparticle delivery systems, and cancer*

JOHN PRIATEL | PhD, Director

- *Honorary Assistant Professor at University of British Columbia*
- *Expertise in lymphocyte biology, inflammation, and cancer*

KARIM NANJI | Director

- *CEO Marble Financial*

QUINN MARTIN | CPA, CFO

- *Principal at DBM CPA*

STOCK INFORMATION

TICKERS: METX:CSE AND Q9T:FSE

KEY FINANCIALS

Share Price (Oct 8, 2025)	$4.00
Shares outstanding	29,589,438
Shares reserved for issuance	7,908,890
Share price: Year high-low	$2.10 - $11.00
Cash – May 31, 2025	$1.65M
Debt – May 31, 2025	Nil
Major shareholders: Management & directors	43%



KEY ANNOUCEMENTS & PUBLICATIONS

October 16, 2025 – ME Therapeutics granted licence for CD22 nanobody asset to expand next-gen in vivo CAR cell therapy program

October 10, 2025 – ME Therapeutics added to CSE25 Index

September 26, 2025 – ME Therapeutics secures U.S. patent for lead candidate and advances broader therapeutic programs

May 21, 2025 – ME Therapeutics receives support to advance mRNA therapeutic candidates for cancer and inflammatory disease

March 3, 2025 – ME Therapeutics Inc announces it has engaged Lucosky Brookman LLP to explore a listing on the Nasdaq or NYSE

January 14, 2025 – ME Therapeutics announces that its first therapeutic mRNA candidate shows encouraging anti-cancer efficacy in vivo

SALIM DHANJI, PH.D

Chief Executive Officer

Address

2665 East Mall
Room 249
Vancouver, British Columbia , Canada
V6T 1Z4

Contact Info

Email: salim@metherapeutics.com

Website

metherapeutics.com

me THERAPEUTICS

Thank You